Similarly, by immunohistochemistry and Western blotting, carriers of the rs13347 variant genotypes (CT and TT) were shown to exhibit dramatically increased CD44 than CC carriers in breast cancer, acute myeloid leukemia, nasopharyngeal carcinoma, and colorectal cancer13, 15, 16, 17. This evidence concerns the gene CD44 and nasopharyngeal carcinoma.